TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1337901

Group type: EXPERIMENTAL
Intervention: Sealapex cement
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: AH26
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tubli‐Seal
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Diaket
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Endomethasone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CRCS
Number of subjects: 150

Group type: COMPARATOR
Intervention: Positive control (gutta‐percha without sealing cement)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Negative control (nail varnish covering apex, root canal empty)
Number of subjects: 150
Study: 3006226

Group type: EXPERIMENTAL
Intervention: Intravenous Acyclovir (ACV) 10 mg/kg every 8 h for 7 days
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (PLO)
Number of subjects: 31
Study: 29113521

Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 30026000

Group type: EXPERIMENTAL
Intervention: Niraparib (300 mg once daily)
Number of subjects: 553

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 553
Study: 26865043

Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading dose, followed by 90 mg twice daily after PCI
Number of subjects: 350

Group type: COMPARATOR
Intervention: Clopidogrel 600 mg loading dose, followed by 75 mg once daily after PCI
Number of subjects: 350
Study: 24196189

Group type: EXPERIMENTAL
Intervention: Sedentary time (SED-time)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous-intensity physical activity (MVPA)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Total physical activity energy expenditure (PAEE)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness
Number of subjects: 394
Study: 22410586

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 100 μg
Number of subjects: 69

Group type: COMPARATOR
Intervention: TAP block with 0.5% ropivacaine 1.5 mg/kg
Number of subjects: 69
Study: 20158973

Group type: EXPERIMENTAL
Intervention: Promotores de salud intervention (8 health classes using the Su Corazón, Su Vida curriculum)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Control group (basic educational materials at baseline, no further intervention)
Number of subjects: 328
Study: 17650631

Group type: EXPERIMENTAL
Intervention: Captopril (Aspharma Co, Anzhero‐Sudzhensk)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capoten (Bristol Myers Squibb Co.; official Russian producer, Akrikhin KhimFarmKombinat)
Number of subjects: 0
Study: 17214388

Group type: EXPERIMENTAL
Intervention: Patellar resurfacing during TKA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-resurfaced patellas
Number of subjects: 0
Study: 14713566

Group type: EXPERIMENTAL
Intervention: Midwife intervention for pregnant and postnatal women
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Brief psychotherapy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Biological interventions
Number of subjects: 19
Study: 10974967

Group type: EXPERIMENTAL
Intervention: Psychological debriefing
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 0
Study: 8839509

Group type: EXPERIMENTAL
Intervention: Beta-carotene with omeprazole (high gastric pH)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Beta-carotene without omeprazole (low gastric pH)
Number of subjects: 12
Study: 1501083

Group type: EXPERIMENTAL
Intervention: Bag-fixated IOLs
Number of subjects: 600

Group type: COMPARATOR
Intervention: Sulcus-fixated IOLs
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Three-piece IOLs (sulcus-fixated)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: One-piece IOLs
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Biconvex design
Number of subjects: 600

Group type: COMPARATOR
Intervention: Plano-convex or laser ridge configurations
Number of subjects: 600
Study: 6339349

Group type: EXPERIMENTAL
Intervention: 0.5 ml HBIG at birth, 3 months, and 6 months
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: 1.0 ml HBIG at birth only
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 31504693

Group type: EXPERIMENTAL
Intervention: Daytime protein (30 g casein) 30 min post-resistance exercise
Number of subjects: 13

Group type: COMPARATOR
Intervention: Presleep placebo (0 g casein) 30 min before bed
Number of subjects: 13
Study: 30653534

Group type: EXPERIMENTAL
Intervention: Vitamin fortified beverage (FB, 1.5ml/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Coloured water (placebo, PL)
Number of subjects: 20
Study: 28587789

Group type: EXPERIMENTAL
Intervention: Once-weekly albiglutide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study: 26060584

Group type: EXPERIMENTAL
Intervention: Active UH-LF-rTMS
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham UH-LF-rTMS
Number of subjects: 18
Study: 23624142

Group type: EXPERIMENTAL
Intervention: Symmetrical sequences (ABCDCBA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asymmetrical sequences (ABCDBCA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Static body postures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental sequences
Number of subjects: 0
Study: 21552073

Group type: EXPERIMENTAL
Intervention: TheraSuit
Number of subjects: 20

Group type: COMPARATOR
Intervention: control suit
Number of subjects: 20
Study: 19916639

Group type: EXPERIMENTAL
Intervention: Intervention group (promoting physical activity and internal motivation for exercise and weight loss)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control group (general health education)
Number of subjects: 239
Study: 17716324

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg BID
Number of subjects: 293

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 293
Study: 14981370

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives with desogestrel (DG/EE)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives with levonorgestrel (LNG/EE)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives with both preparations (LNG/EE and DG/EE)
Number of subjects: 35
Study: 11712093

Group type: EXPERIMENTAL
Intervention: Artesunate (n=528) or artemether (n=11)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Re-treatment with artemisinin
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Artemisinin treatment
Number of subjects: 461

Group type: COMPARATOR
Intervention: Birth outcomes
Number of subjects: 461
Study: 9151026

Group type: EXPERIMENTAL
Intervention: Heparin treated circuits (Duraflo II)
Number of subjects: 805

Group type: COMPARATOR
Intervention: Untreated circuit
Number of subjects: 805
Study: 7951083

Group type: EXPERIMENTAL
Intervention: Berodual (1 dose = 0.02 mg ipratropium bromide + 0.05 mg fenoterol), administered 3 x 1 dose/daily for 14 days
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (Atrovent, 1 dose = 0.02 mg), administered 3 x 2 doses/daily for 14 days
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fenoterol (Berotec, 1 dose = 0.2 mg), administered 3 x 2 doses/daily for 14 days
Number of subjects: 14
Study: 3616916

Group type: EXPERIMENTAL
Intervention: Problem-oriented small group sessions (POSGS) on thyroid disease
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Problem-oriented small group sessions (POSGS) on breast disease
Number of subjects: 42

Group type: COMPARATOR
Intervention: Didactic lectures (DL) on thyroid disease
Number of subjects: 42

Group type: COMPARATOR
Intervention: Didactic lectures (DL) on breast disease
Number of subjects: 42
Study: 29303771

Group type: EXPERIMENTAL
Intervention: Medium-term biological variation assessment (blood sampling once/week for five consecutive weeks)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Short-term biological variation assessment (blood sampling once/day for five consecutive days)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Reference change values (RCV) for RBC and reticulocyte parameters
Number of subjects: 43
Study: 26608702

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study: 25397624

Group type: EXPERIMENTAL
Intervention: Desloratadine-montelukast (10mg/d montelukast and 5mg/d desloratadine for 6 weeks)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Untreated patients (no intervention)
Number of subjects: 64
Study: 23531349

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 2615

Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg
Number of subjects: 2615

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2615

Group type: COMPARATOR
Intervention: Interferon beta
Number of subjects: 2615
Study: 20373015

Group type: EXPERIMENTAL
Intervention: Frozen Embryo Transfer (FET)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Fresh Embryo Transfer (ET)
Number of subjects: 374
Study: 19040343

Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 0
Study: 17217716

Group type: EXPERIMENTAL
Intervention: Dobutamine infusion (10 microg kg‐1 min‐1, increasing to 40 microg kg‐1 min‐1 at 3 min intervals)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dobutamine infusion
Number of subjects: 8
Study: 14594938

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy (HF group), fraction size 1.2 Gy, mean total dose 73.4 Gy (range, 66-79.2 Gy)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy (HF group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional fractionated radiation therapy (CF group), fraction size 1.8-2.0 Gy, mean total dose 65.4 Gy (range, 60-70 Gy)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional fractionated radiation therapy (CF group)
Number of subjects: 42
Study: 10981168

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme (ACE) inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9105649

Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 50

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 50
Study: 7901585

Group type: EXPERIMENTAL
Intervention: Albendazole (10 mg/kg daily) for 1 month (group A)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Albendazole (10 mg/kg daily) for about 3 months (group B)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no albendazole treatment)
Number of subjects: 55
Study: 2939116

Group type: EXPERIMENTAL
Intervention: etodolac 50‐600 mg/d
Number of subjects: 1382

Group type: EXPERIMENTAL
Intervention: etodolac
Number of subjects: 1382

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1382
Study: 31811742

Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF) + Connective tissue graft (CTG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF) alone
Number of subjects: 30
Study: 29738635

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal packing
Number of subjects: 47

Group type: COMPARATOR
Intervention: Hypopharyngeal packing
Number of subjects: 47
Study: 28153824

Group type: EXPERIMENTAL
Intervention: Brincidofovir
Number of subjects: 27

Group type: COMPARATOR
Intervention: Cidofovir
Number of subjects: 27
Study: 25085036

Group type: EXPERIMENTAL
Intervention: Sevoflurane (8% for induction, maintained at 2-4%)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ketamine (1 mg/kg bolus)
Number of subjects: 24
Study: 23172975

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (RT-CGM)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose (control)
Number of subjects: 50
Study: 20965514

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nontreated (Control)
Number of subjects: 60
Study: 18180681

Group type: EXPERIMENTAL
Intervention: Lotrafilcon A lenses
Number of subjects: 53

Group type: COMPARATOR
Intervention: Balafilcon A lenses
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Daily-wear basis
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Continuous-wear basis
Number of subjects: 53
Study: 16385384

Group type: COMPARATOR
Intervention: s.c. infusion of saline (SAL)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: s.c. infusion of GLP‐1 (2.4 pmol kg(‐1) min(‐1); LSC)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: s.c. infusion of GLP‐1 (2.4 pmol kg(‐1) min(‐1)) in combination with a DPP‐4 inhibitor (IB)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: i.v. infusion of GLP‐1 (1.2 pmol kg(‐1) min(‐1); IV)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: s.c. infusion of GLP‐1 (9.6 pmol kg(‐1) min(‐1); HSC)
Number of subjects: 7
Study: 12529091

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 1711

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1711
Study: 10678544

Group type: EXPERIMENTAL
Intervention: Adrenomedullin (3 pmol/kg per min)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 9118626

Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate 0.05%
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 1:4 dilution of betamethasone dipropionate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Ointment base (control)
Number of subjects: 14
Study: 1633753

Group type: EXPERIMENTAL
Intervention: Triazolam (0.32 mg/70 kg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Triazolam (0.1‐0.75 mg/70 kg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 6241386

Group type: EXPERIMENTAL
Intervention: Transluminal coronary angioplasty (group I)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Conservative treatment (group II)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Transluminal coronary angioplasty
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Total coronary occlusion treatment
Number of subjects: 107
Study: 30521147

Group type: EXPERIMENTAL
Intervention: Chicken breast consumption
Number of subjects: 0
Study: 30202408

Group type: EXPERIMENTAL
Intervention: Gross myofascial release (MFR) of neck and upper limb in addition to conventional therapy (hot moist pack, TENS, stretching and strengthening exercises) for 6 consecutive days.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional treatment (hot moist pack, TENS, stretching and strengthening exercises) for 6 consecutive days.
Number of subjects: 40
Study: 26446709

Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy (CBT)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Schema therapy (ST)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 69
Study: 24489043

Group type: EXPERIMENTAL
Intervention: Well London community engagement programme
Number of subjects: 3986
Study: 21320855

Group type: EXPERIMENTAL
Intervention: High volume feeds at 300 ml/kg/day
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard volume feeds at 200 ml/kg/day
Number of subjects: 64
Study: 20561621

Group type: EXPERIMENTAL
Intervention: Low-volume PEG + ascorbic acid
Number of subjects: 895

Group type: COMPARATOR
Intervention: Standard-volume PEG-electrolyte solution
Number of subjects: 895

Group type: EXPERIMENTAL
Intervention: Split-dosage regimen
Number of subjects: 895

Group type: EXPERIMENTAL
Intervention: Fair/poor preparation
Number of subjects: 895

Group type: COMPARATOR
Intervention: Non-split-dosage arm
Number of subjects: 895

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 895

Group type: EXPERIMENTAL
Intervention: Non-split-dosage bowel preparation schedule
Number of subjects: 895
Study: 17439381

Group type: EXPERIMENTAL
Intervention: TLC diet plus soy nuts (25 g soy protein and 101 mg aglycone isoflavones)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: TLC diet plus soy nuts
Number of subjects: 60

Group type: COMPARATOR
Intervention: TLC diet alone
Number of subjects: 60
Study: 15785257

Group type: EXPERIMENTAL
Intervention: Spinal manipulation (thrust technique)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Postisometric relaxation (mobilization)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 12409574

Group type: EXPERIMENTAL
Intervention: Unidimensional technique
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Bidimensional technique
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Volumetric technique
Number of subjects: 38
Study: 11443509

Group type: EXPERIMENTAL
Intervention: Average-adulthood BMI as a mortality predictor
Number of subjects: 14407

Group type: EXPERIMENTAL
Intervention: Baseline BMI as a covariate
Number of subjects: 14407

Group type: EXPERIMENTAL
Intervention: BMI <20 kg/m2
Number of subjects: 14407
Study: 9399714

Group type: EXPERIMENTAL
Intervention: Laser guidewire (LW)
Number of subjects: 345
Study: 7956713

Group type: EXPERIMENTAL
Intervention: Diabetic patients (n=15)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control subjects (n=6)
Number of subjects: 21
Study: 3628830

Group type: EXPERIMENTAL
Intervention: Apomorphine (0.5 mg sc)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30260273

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg) administered via intravenous infusion
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Ketamine responders
Number of subjects: 84
Study: 27695423

Group type: EXPERIMENTAL
Intervention: Resveratrol supplementation (200 mg/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (200 mg/day)
Number of subjects: 19
Study: 25624757

Group type: EXPERIMENTAL
Intervention: Intensive cycle ergometer exercise program
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study: 23619342

Group type: EXPERIMENTAL
Intervention: Se‐75‐homocholic acid taurine (Se‐75‐HCAT) administered orally
Number of subjects: 16
Study: 20350153

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) as a full-mouth procedure after scaling and root planing (SRP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group treated with photosensitizer solution without laser irradiation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PDT group
Number of subjects: 24
Study: 19052402

Group type: EXPERIMENTAL
Intervention: Azathioprine 100 mg daily (group A)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Betamethasone 2 mg daily (group B)
Number of subjects: 55
Study: 15876902

Group type: EXPERIMENTAL
Intervention: Citalopram 40 mg/d
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 12505565

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 2044

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2044
Study: 10380021

Group type: EXPERIMENTAL
Intervention: Intravenous 500 mg acetazolamide (Diamox) (Group 1)
Number of subjects: 63

Group type: COMPARATOR
Intervention: No treatment (Group 2)
Number of subjects: 63
Study: 8701509

Group type: EXPERIMENTAL
Intervention: Hot water irrigation (HWI)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Tamponade
Number of subjects: 44
Study: 1998656

Group type: EXPERIMENTAL
Intervention: niacin/colestipol therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Panel-determined consensus score
Number of subjects: 0
Study: 31786871

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Three-dimensional conformal radiotherapy (3DCRT)
Number of subjects: 95
Study: 30089614

Group type: EXPERIMENTAL
Intervention: Highest oxLDL quartile (≥28.81 μg/dL)
Number of subjects: 3019

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 3019
Study: 27329869

Group type: COMPARATOR
Intervention: Palacos bone cement
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Palamed bone cement
Number of subjects: 39
Study: 24999157

Group type: EXPERIMENTAL
Intervention: Combined albendazole (15 mg/kg per day) plus praziquantel (50 mg/kg per day)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Standard albendazole (15 mg/kg per day)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Increased dose albendazole (22.5 mg/kg per day)
Number of subjects: 124
Study: 22553354

Group type: EXPERIMENTAL
Intervention: Betulinic acid (1 to 10 μmol/L)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: RNA interference knockdown of Sp1, Sp3, Sp4
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Betulinic acid
Number of subjects: 2
Study: 19756506

Group type: EXPERIMENTAL
Intervention: Original SAPS 3
Number of subjects: 1873

Group type: EXPERIMENTAL
Intervention: Customized SAPS 3 (SAPS 3-AUS)
Number of subjects: 1873
Study: 17976264

Group type: EXPERIMENTAL
Intervention: Dextrose solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beef drink
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shepherd's pie (solid meal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liquid foods (dextrose and beef drinks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Solid meal (shepherd's pie)
Number of subjects: 0
Study: 16088266

Group type: EXPERIMENTAL
Intervention: Multidisciplinary treatment and repeated thermal therapy (far-infrared ray dry sauna therapy and post-sauna warming, once a day for 4 weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Multidisciplinary treatment (cognitive behavioral therapy, rehabilitation, and exercise therapy)
Number of subjects: 46
Study: 12805913

Group type: EXPERIMENTAL
Intervention: Lidocaine (600 mg + 5 mg/ml adrenaline)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mepivacaine (600 mg + 5 microg/ml adrenaline)
Number of subjects: 30
Study: 9505892

Group type: EXPERIMENTAL
Intervention: High dose enteric coated pancreatin enzyme supplementation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 7893297

Group type: EXPERIMENTAL
Intervention: LAT (4% lidocaine, 1:2,000 adrenaline, 1% tetracaine)
Number of subjects: 95

Group type: COMPARATOR
Intervention: TAC (0.5% tetracaine, 1:2,000 adrenaline, 11.8% cocaine)
Number of subjects: 95